Department of Nutrition and Health, Universidade Federal de Viçosa, Viçosa, Minas Gerais, Brazil.
Nutr Rev. 2019 Oct 1;77(10):725-734. doi: 10.1093/nutrit/nuz034.
Consumption of dietary advanced glycation end products (AGEs) is associated with oxidative stress, inflammation, and other chronic conditions commonly associated with obesity.
To analyze the effects of dietary AGEs on complications associated with obesity.
This systematic review was conducted and reported according to PRISMA guidelines. The PubMed, Cochrane, and Scopus databases were searched, using the terms "advanced glycation end products," "overweight," and "obesity." The last search was performed in October 2018.
Six studies that evaluated the effects of low-AGE and high-AGE diets were included in the review. The duration of the studies ranged from 1 day to 12 weeks. A comparison of all the compiled data was conducted by the authors.
Circulating and urinary AGE markers, besides soluble receptor for AGEs, were considered as the primary outcomes. The secondary outcomes were cardiometabolic, inflammatory, glycemic, anthropometric, and renal markers.
AGE-RAGE interactions can activate the NF-κB (nuclear factor kappa B) signaling pathway and inhibit the PI3K-AKT pathway in adipocytes, which may explain their association with chronic diseases. This interaction can be considered as a novel explanation for the pathogenesis of obesity. AGEs can also be used as a biomarker for monitoring responses to dietary interventions in overweight and obese people.
PROSPERO registration no. CRD42018082745.
饮食中晚期糖基化终产物（AGEs）的消耗与氧化应激、炎症和其他与肥胖相关的慢性疾病有关。
分析饮食 AGEs 对肥胖相关并发症的影响。
本系统评价按照 PRISMA 指南进行和报告。在 PubMed、Cochrane 和 Scopus 数据库中，使用术语“advanced glycation end products”、“overweight”和“obesity”进行检索。最后一次检索于 2018 年 10 月进行。
有 6 项研究评估了低 AGE 和高 AGE 饮食的影响，被纳入综述。研究的持续时间从 1 天到 12 周不等。作者对所有综合数据进行了比较。
循环和尿 AGE 标志物，以及可溶性 AGE 受体，被认为是主要结果。次要结果是心血管代谢、炎症、血糖、人体测量学和肾脏标志物。
AGE-RAGE 相互作用可激活脂肪细胞中的 NF-κB（核因子 kappa B）信号通路并抑制 PI3K-AKT 通路，这可以解释它们与慢性疾病的关系。这种相互作用可以被认为是肥胖发病机制的一种新解释。AGEs 也可以作为监测超重和肥胖人群对饮食干预反应的生物标志物。
PROSPERO 注册号 CRD42018082745。
